• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经典型霍奇金淋巴瘤患者外周血和肿瘤微环境中的免疫生物标志物与肿瘤负荷及治疗反应的关系

Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment.

作者信息

Mulder Tom A, Andersson Maria L, Peña-Pérez Lucía, Heimersson Kia, Xagoraris Ioanna, Wahlin Björn E, Månsson Robert, Hansson Lotta, Rassidakis Georgios, Palma Marzia

机构信息

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.

出版信息

Hemasphere. 2022 Oct 26;6(11):e794. doi: 10.1097/HS9.0000000000000794. eCollection 2022 Nov.

DOI:10.1097/HS9.0000000000000794
PMID:36325271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9619233/
Abstract

In classical Hodgkin lymphoma (cHL), the malignant cells represent only a small fraction of the tumor. Yet, they orchestrate a lymphocyte-dominated tumor microenvironment (TME) that supports their survival and growth. The systemic effects of this local immunomodulation are not fully elucidated. Here, we aimed at characterizing circulating lymphocytes and plasma proteins in relation to clinical parameters and treatment effect. Peripheral blood (PB) samples were obtained from 48 consecutive patients at diagnosis and at 2 time points after successful primary treatment. Single-cell suspensions were prepared from lymph node (LN) biopsies obtained for routine diagnostic purposes. Twenty healthy individuals were included as controls. Cells from PB and LN were analyzed by flow cytometry, and plasma proteins by Proximity Extension Assay. We found that the frequencies of T and B cells positively correlated between the LN and the PB compartments. Compared to controls, cHL patients had higher frequencies of proliferating T cells as well as higher expression of programmed death (PD)-1 and cytotoxic T lymphocyte antigen (CTLA)-4 in circulating T cells, and lower naive T-cell frequencies. Advanced-stage patients had fewer NK cells with a functionally impaired phenotype. Differences in the immune profile were observed in patients with a high tumor burden and with high inflammation, respectively. Most of these deviations disappeared after standard first-line treatment. Patients who received radiotherapy involving the mediastinum had low T-cell counts for a prolonged period. Our findings suggest that the immunomodulation of lymphocytes in the TME of cHL might affect immune biomarkers in the PB.

摘要

在经典型霍奇金淋巴瘤(cHL)中,恶性细胞仅占肿瘤的一小部分。然而,它们精心构建了一个以淋巴细胞为主导的肿瘤微环境(TME),以支持其存活和生长。这种局部免疫调节的全身效应尚未完全阐明。在此,我们旨在表征与临床参数和治疗效果相关的循环淋巴细胞和血浆蛋白。在诊断时以及成功进行初始治疗后的2个时间点,从48例连续患者中获取外周血(PB)样本。从用于常规诊断目的的淋巴结(LN)活检组织中制备单细胞悬液。纳入20名健康个体作为对照。通过流式细胞术分析PB和LN中的细胞,并通过邻近延伸分析检测血浆蛋白。我们发现,LN和PB区室中T细胞和B细胞的频率呈正相关。与对照组相比,cHL患者循环T细胞中增殖T细胞的频率更高,程序性死亡(PD)-1和细胞毒性T淋巴细胞抗原(CTLA)-4的表达也更高,而幼稚T细胞频率更低。晚期患者的NK细胞较少,且具有功能受损的表型。分别在肿瘤负荷高和炎症反应高的患者中观察到免疫谱的差异。在标准一线治疗后,这些偏差大多消失。接受纵隔放疗的患者在较长时间内T细胞计数较低。我们的研究结果表明,cHL的TME中淋巴细胞的免疫调节可能会影响PB中的免疫生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d9/9619233/509174077dd5/hs9-6-e794-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d9/9619233/176183e73a71/hs9-6-e794-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d9/9619233/4056c8de9d9f/hs9-6-e794-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d9/9619233/563ac62d3ce0/hs9-6-e794-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d9/9619233/93bb10343c1e/hs9-6-e794-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d9/9619233/344e2b5ede12/hs9-6-e794-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d9/9619233/509174077dd5/hs9-6-e794-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d9/9619233/176183e73a71/hs9-6-e794-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d9/9619233/4056c8de9d9f/hs9-6-e794-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d9/9619233/563ac62d3ce0/hs9-6-e794-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d9/9619233/93bb10343c1e/hs9-6-e794-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d9/9619233/344e2b5ede12/hs9-6-e794-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9d9/9619233/509174077dd5/hs9-6-e794-g006.jpg

相似文献

1
Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment.经典型霍奇金淋巴瘤患者外周血和肿瘤微环境中的免疫生物标志物与肿瘤负荷及治疗反应的关系
Hemasphere. 2022 Oct 26;6(11):e794. doi: 10.1097/HS9.0000000000000794. eCollection 2022 Nov.
2
Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.单细胞分析揭示了 CXCL13/CXCR5 轴生物学在富含淋巴细胞的经典霍奇金淋巴瘤中的重要性。
Proc Natl Acad Sci U S A. 2021 Oct 12;118(41). doi: 10.1073/pnas.2105822118.
3
Mass cytometry of Hodgkin lymphoma reveals a CD4 regulatory T-cell-rich and exhausted T-effector microenvironment.霍奇金淋巴瘤的液滴式细胞术分析显示富含 CD4 调节性 T 细胞和耗竭的 T 效应细胞的微环境。
Blood. 2018 Aug 23;132(8):825-836. doi: 10.1182/blood-2018-04-843714. Epub 2018 Jun 7.
4
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.经典型霍奇金淋巴瘤接受抗 PD-1 治疗后出现肿瘤和微环境反应,但无细胞毒性 T 细胞激活。
Blood. 2020 Dec 17;136(25):2851-2863. doi: 10.1182/blood.2020008553.
5
Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma.霍奇金淋巴瘤恶性前阶段的 T 细胞炎症免疫反应的前体细胞及其意义。
Immunobiology. 2020 Jan;225(1):151872. doi: 10.1016/j.imbio.2019.11.007. Epub 2019 Nov 25.
6
Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue.经典型霍奇金淋巴瘤肿瘤诊断组织中的免疫蛋白质组分析
Cancers (Basel). 2021 Dec 21;14(1):9. doi: 10.3390/cancers14010009.
7
The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.经典型霍奇金淋巴瘤的微环境龛中富含 CTLA-4 阳性、PD-1 阴性的 T 细胞。
Blood. 2019 Dec 5;134(23):2059-2069. doi: 10.1182/blood.2019002206.
8
Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients.淋巴瘤患者外周血中免疫调节细胞的表型改变。
BMC Cancer. 2019 Apr 5;19(1):316. doi: 10.1186/s12885-019-5529-0.
9
Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.IV期转移性炎性乳腺癌患者的免疫表型
Breast Cancer Res. 2020 Dec 2;22(1):134. doi: 10.1186/s13058-020-01371-x.
10
The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.成人和儿童霍奇金淋巴瘤肿瘤微环境的电路:细胞组成、细胞因子谱、EBV 和外泌体。
Cancer Rep (Hoboken). 2021 Apr;4(2):e1311. doi: 10.1002/cnr2.1311. Epub 2020 Oct 26.

引用本文的文献

1
Sulforaphane promotes natural killer cell-mediated anti-tumor immune responses partially via cGAS-STING pathway in classical Hodgkin lymphoma.萝卜硫素在经典型霍奇金淋巴瘤中部分通过cGAS-STING途径促进自然杀伤细胞介导的抗肿瘤免疫反应。
Leukemia. 2025 Jul;39(7):1787-1790. doi: 10.1038/s41375-025-02627-1. Epub 2025 Apr 28.
2
Prognostic value of a novel myeloid-to-lymphoid ratio biomarker in advanced gastric cancer.一种新型髓系与淋巴细胞比值生物标志物在晚期胃癌中的预后价值
Clin Transl Oncol. 2025 Mar;27(3):1118-1130. doi: 10.1007/s12094-024-03612-3. Epub 2024 Aug 14.
3
Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma.

本文引用的文献

1
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma.抗 PD-1 一线治疗霍奇金淋巴瘤中循环淋巴细胞衰竭表型逆转作为免疫相关性标志物。
Leukemia. 2022 Mar;36(3):760-771. doi: 10.1038/s41375-021-01421-z. Epub 2021 Sep 28.
2
Radiation-induced lung injury: current evidence.放射性肺损伤:当前证据。
BMC Pulm Med. 2021 Jan 6;21(1):9. doi: 10.1186/s12890-020-01376-4.
3
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma.
在霍奇金淋巴瘤中,采用 Brentuximab Vedotin 联合伊匹单抗和/或纳武单抗治疗耐药的肿瘤免疫特征。
Cancer Res Commun. 2024 Jul 1;4(7):1726-1737. doi: 10.1158/2767-9764.CRC-24-0252.
4
Co-inhibition of adenosine 2b receptor and programmed death-ligand 1 promotes the recruitment and cytotoxicity of natural killer cells in oral squamous cell carcinoma.腺苷 2b 受体和程序性死亡配体 1 的共抑制促进口腔鳞状细胞癌中自然杀伤细胞的募集和细胞毒性。
PeerJ. 2023 Aug 30;11:e15922. doi: 10.7717/peerj.15922. eCollection 2023.
经典型霍奇金淋巴瘤患者对 PD-1 阻断治疗反应的外周免疫特征。
Nat Med. 2020 Sep;26(9):1468-1479. doi: 10.1038/s41591-020-1006-1. Epub 2020 Aug 10.
4
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.对分选的霍奇金 Reed-Sternberg 细胞进行基因组分析揭示了免疫逃逸的互补机制。
Blood Adv. 2019 Dec 10;3(23):4065-4080. doi: 10.1182/bloodadvances.2019001012.
5
Human peripheral blood DNAM-1 NK cells are a terminally differentiated subset with limited effector functions.人类外周血 DNAM-1 NK 细胞是终末分化的亚群,具有有限的效应功能。
Blood Adv. 2019 Jun 11;3(11):1681-1694. doi: 10.1182/bloodadvances.2018030676.
6
Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma.PD-L1 介导的反向信号促进经典型霍奇金淋巴瘤中恶性细胞的生长和存活。
Blood Cancer J. 2019 Feb 19;9(3):22. doi: 10.1038/s41408-019-0185-9.
7
Risk factors and clinical characteristics of Pneumocystis jirovecii pneumonia in lung cancer.肺癌患者肺孢子菌肺炎的危险因素和临床特征。
Sci Rep. 2019 Feb 14;9(1):2094. doi: 10.1038/s41598-019-38618-3.
8
Mass cytometry of Hodgkin lymphoma reveals a CD4 regulatory T-cell-rich and exhausted T-effector microenvironment.霍奇金淋巴瘤的液滴式细胞术分析显示富含 CD4 调节性 T 细胞和耗竭的 T 效应细胞的微环境。
Blood. 2018 Aug 23;132(8):825-836. doi: 10.1182/blood-2018-04-843714. Epub 2018 Jun 7.
9
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.NK 细胞和单核细胞/巨噬细胞上的 PD-1/PD-L1 免疫逃逸在霍奇金淋巴瘤中比 DLBCL 更为显著。
Blood. 2018 Apr 19;131(16):1809-1819. doi: 10.1182/blood-2017-07-796342. Epub 2018 Feb 15.
10
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.PET 引导治疗晚期霍奇金淋巴瘤(HD18):德国霍奇金研究组开展的一项开放标签、国际、随机 3 期临床试验的最终结果。
Lancet. 2017 Dec 23;390(10114):2790-2802. doi: 10.1016/S0140-6736(17)32134-7. Epub 2017 Oct 20.